Lung cancer is a leading cause of cancer-related mortality worldwide, and is classically
divided into two major histological subtypes: non-small-cell lung cancer (NSCLC) and small …

Background Immune checkpoint inhibitors are effective cancer treatments, but molecular
determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies …

Simple Summary It is already known that DNA alterations do not fully recapitulate the
complex nature of a tumor or its potential interaction with specific treatments. Therefore, in …

Cancer types are commonly classified by histopathology and more recently through
molecular characteristics such as gene expression, mutations, copy number variations and …

Objectives: Lung adenocarcinoma (LUAD) accounts for a majority of cancer-related deaths
worldwide annually. The identification of prognostic biomarkers and prediction of prognosis …

Purpose: New prognostic markers to guide treatment decisions in early stage non–small cell
lung cancer are necessary to improve patient outcomes. In this report, we assess the utility of …

The enrichment of cancer stem cell (CSC)-like cellular states has not previously been
considered to be a causative mechanism in the generalized progression of EGFR-mutant …

Background: Accurate survival stratification in early-stage non–small cell lung cancer
(NSCLC) could inform the use of adjuvant therapy. We developed a clinically implementable …

The machine learning based techniques for detection of lungs cancer can assist the
clinicians in assessing the risk of pulmonary nodules being malignant. We are developing …

Lung adenocarcinoma patients of similar clinical stage and undergoing the same treatments
often have marked interindividual variations in prognosis. These clinical discrepancies may …